Biomarker treatment effects in two phase 3 trials of gantenerumab. Bittner T, Tonietto M, Klein G, Belusov A, et al. Alzheimers Dement 2025;21:e14414.

Read + Share

Amedeo Smart

Independent Medical Education

Bittner T, Tonietto M, Klein G, Belusov A, et al. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement 2025;21:e14414.
PMID: 39887500